Research Comparison
Cagrilintide (AM833) vs Survodutide
A side-by-side research comparison of Cagrilintide (AM833) and Survodutide drawn from DRPSHP' peptide database records.
Cagrilintide (AM833)
Native human amylin is a poor research tool: the 37-residue hormone that pancreatic beta cells release alongside insulin aggregates readily and does not last long in circulation. Analogues are engineered to get round both problems, and Cagrilintide is one of them — a synthetic amylin analogue carrying a fatty-acid side chain that binds albumin in blood, which lengthened its half-life in pharmacokinetic studies. It is described as acting at amylin receptors and at the calcitonin receptor. Animal work was followed by human clinical trials in metabolic research, both of the compound alone and alongside a GLP-1 receptor agonist. Set against the literature on amylin itself, the published pharmacology of this analogue is recent and narrow.
Survodutide
Survodutide (development code BI 456906) belongs to a design family that pairs glucagon receptor activation with GLP-1 receptor activation in one molecule; related triple agonists add the GIP receptor to the mix. It is a lipidated peptide, meaning a fatty-acid chain has been attached to extend its time in circulation, a device shared by other long-acting peptides of this type. Its record spans receptor assays, rodent work and human trials aimed at metabolic and liver conditions. Relative to older incretin compounds the peer-reviewed literature is brief and recent, so conclusions remain provisional.
Reading a comparison
A comparison places two records side by side; it does not merge them. Each description above is drawn from that compound's own record, and the two were not necessarily characterised by the same methods, at the same time, or to the same level of detail. Before comparing any attribute, it is worth establishing that both records describe the substance you think they describe — names are not identifiers, and two entries sharing a name can differ in salt form, stereochemistry or the convention used to state a mass. Where a figure carries no method beside it, the comparison is between two reported numbers rather than between two measurements.